Jane Street’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Jane Street’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-9,959	Closed	-$749K	–	10911
2022 Q2	$749K	Buy	+9,959	New	+$443K	﹤0.01%	6011
2022 Q1	–	Sell	-9,121	Closed	-$435K	–	11418
2021 Q4	$435K	Sell	9,121 -1,392	-13%	-$62.2K	﹤0.01%	7513
2021 Q3	$698K	Buy	10,513 +1,545	+17%	+$110K	﹤0.01%	6647
2021 Q2	$700K	Sell	8,968 -287	-3%	-$21.2K	﹤0.01%	6592
2021 Q1	$875K	Sell	9,255 -13,625	-60%	-$1.62M	﹤0.01%	5708
2020 Q4	$2.79M	Buy	22,880 +10,491	+85%	+$1.15M	﹤0.01%	2919
2020 Q3	$1.08M	Buy	12,389 +7,262	+142%	+$506K	﹤0.01%	3976
2020 Q2	$332K	Buy	+5,127	New	+$296K	﹤0.01%	5684
2020 Q1	–	Sell	-6,674	Closed	-$416K	–	6228
2019 Q4	$416K	Buy	+6,674	New	+$318K	﹤0.01%	3908

Jane Street's TPTX Position: Q3 2022 in Review

Jane Street sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 9,959 shares — an estimated $749K sold.

Jane Street first reported a position in TPTX in Q4 2019 and held it in 9 quarters. The position peaked at $2.79M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Jane Street reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Jane Street sold 9,959 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $749K.
Jane Street first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 9 quarters.
Jane Street's Turning Point Therapeutics, Inc. Common Stock position peaked at $2.79M in Q4 2020.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Jane Street's 13F filing for Q3 2022, filed 15 Nov 2022.